Patient characteristics
| Patient | Age | Sex | Mutations | Neutrophil count | NK cell count | Treatment with G-CSF |
| yr | cells/µl | cells/µl | ||||
| 1 | 24 | F | SCN ELANE | 860 | 136 | + |
| 2 | 2 | F | SCN ELANE | 58 | 121 | + |
| 3 | 3 | F | SCN ELANE | ND | 167 | − |
| 4 | 34 | F | SCN ELANE | ND | 210 | − |
| 5 | 5 | F | SCN ELANE | 1,400 | 267 | + |
| 6 | 5 | F | SCN ELANE | 2,500 | 285 | + |
| 7 | 2 | F | SCN ELANE | 100 | 483 | + |
| 8 | 30 | F | SCN ELANE | 1,300 | 198 | − |
| 9 | 33 | F | SCN ELANE | 360 | 85 | − |
| 10 | 3 | M | SCN ELANE | 590 | 186 | − |
| 11 | 36 | F | SCN ELANE | 60 | 144 | − |
| 12 | 21 | F | SCN unidentified | 4,624 | 154 | + |
| 13 | 4 | F | SCN unidentified | 425 | 258 | − |
| 14 | 19 | F | SCN unidentified | 1363 | 200 | + |
| 15 | 9 | F | SCN unidentified | 264 | 184 | − |
| 16 | 4 | M | SCN unidentified | 440 | 112 | − |
| 17 | 0.4 | F | SCN unidentified | 920 | 240 | − |
| 18 | 0.5 | M | SCN unidentified | 490 | 87 | − |
| 19 | 60 | M | SCN unidentified | 540 | 29 | − |
| 20 | 3 | M | SCN unidentified | 230 | 313 | − |
| 21 | 22 | F | SCN unidentified | 170 | 75 | − |
| 22 | 1 | F | SCN unidentified | 460 | 605 | − |
| 23 | 1 | F | AIN | 0 | 384 | − |
| 24 | 1.2 | F | AIN | 370 | 943 | − |
| 25 | 3 | F | AIN | 1010 | 104 | − |
| 26 | 3 | F | AIN | 1530 | 276 | − |
| 27 | 5 | F | AIN | 160 | 207 | − |
| 28 | 2 | M | AIN | 550 | 339 | − |
| Patient | Age | Sex | Mutations | Neutrophil count | NK cell count | Treatment with G-CSF |
| yr | cells/µl | cells/µl | ||||
| 1 | 24 | F | SCN ELANE | 860 | 136 | + |
| 2 | 2 | F | SCN ELANE | 58 | 121 | + |
| 3 | 3 | F | SCN ELANE | ND | 167 | − |
| 4 | 34 | F | SCN ELANE | ND | 210 | − |
| 5 | 5 | F | SCN ELANE | 1,400 | 267 | + |
| 6 | 5 | F | SCN ELANE | 2,500 | 285 | + |
| 7 | 2 | F | SCN ELANE | 100 | 483 | + |
| 8 | 30 | F | SCN ELANE | 1,300 | 198 | − |
| 9 | 33 | F | SCN ELANE | 360 | 85 | − |
| 10 | 3 | M | SCN ELANE | 590 | 186 | − |
| 11 | 36 | F | SCN ELANE | 60 | 144 | − |
| 12 | 21 | F | SCN unidentified | 4,624 | 154 | + |
| 13 | 4 | F | SCN unidentified | 425 | 258 | − |
| 14 | 19 | F | SCN unidentified | 1363 | 200 | + |
| 15 | 9 | F | SCN unidentified | 264 | 184 | − |
| 16 | 4 | M | SCN unidentified | 440 | 112 | − |
| 17 | 0.4 | F | SCN unidentified | 920 | 240 | − |
| 18 | 0.5 | M | SCN unidentified | 490 | 87 | − |
| 19 | 60 | M | SCN unidentified | 540 | 29 | − |
| 20 | 3 | M | SCN unidentified | 230 | 313 | − |
| 21 | 22 | F | SCN unidentified | 170 | 75 | − |
| 22 | 1 | F | SCN unidentified | 460 | 605 | − |
| 23 | 1 | F | AIN | 0 | 384 | − |
| 24 | 1.2 | F | AIN | 370 | 943 | − |
| 25 | 3 | F | AIN | 1010 | 104 | − |
| 26 | 3 | F | AIN | 1530 | 276 | − |
| 27 | 5 | F | AIN | 160 | 207 | − |
| 28 | 2 | M | AIN | 550 | 339 | − |
The SCN patients (n = 22; median age = 5 yr; range = 0.4–60) and AIN patients (n = 6; median age = 2.6 yr; range = 1–5) described were analyzed and compared with healthy control individuals (n = 25; median = 30 yr; range = 22–55). ND, not determined.